Dose: 1200 mg twice a day
Single Dose: 1200 (1200)
Frequency: As recommended.
Route: Oral
Instructions: For liquid filled capsules

. It is of Synthetic origin. . The Molecular Weight of Amprenavir is 505.63.

Amprenavir is contraindicated in conditions like Pregnancy,Liver damage,Kidney disease,Breast feeding.

The symptomatic adverse reactions produced by Amprenavir are more or less tolerable and if they become severe, they can be treated symptomatically, these include Flatulence, Dizziness, Headache, Fatigue, Diarrhea, Abdominal pain, Rashes, Pruritus, Hypotension, Depression, Nausea and vomiting, Hypersensitivity reactions, GI disturbance, Blood disorders including anemia, and neutropenia.

Amprenavir is primarily indicated in conditions like Gastric acid reduction during anaesthesia, HIV infection in combination with other antiretroviral drugs.

Amprenavir is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAbacavirAlprazolamIncreased risk of prolonged sedation and respiratory depression when Amprenavir given with Alprazolam.Amiodarone (HCl)Amprenavir possibly increases plasma concentration of Lignocaine; increased risk of ventricular arrhythmias. ADVICE: Avoid concomitant use.MajorAtorvastatinAmprenavir possibly increases plasma concentration of Atorvastatin. ADVICE: Avoid concomitant use. MajorCilostazoleAmprenavir possibly increases plasma concentration of Cilostazol. ADVICE: Avoid concomitant use.Clorazepate (K)Increased risk of prolonged sedation and respiratory depression when Amprenavir given with Clorazepate.MajorDapsoneAmprenavir possibly increases plasma concentration of Dapsone.MajorDiazepamIncreased risk of prolonged sedation and respiratory depression when Amprenavir given with Diazepam.MajorErgotamine (Tartrate)Increased risk of ergotism when Amprenavir given with Ergotamine. ADVICE: Avoid concomitant use.MajorErythromycinPlasma concentration of both drugs increased when Amprenavir given with Erythromycin.MajorFlecainide (Acetate)Amprenavir possibly increases plasma concentration of Flecainide; increased risk of ventricular arrhythmias. ADVICE: Avoid concomitant use.MajorFlurazepam (HCl)Increased risk of prolonged sedation and respiratory depression when Amprenavir given with Flurazepam.LignocaineAmprenavir possibly increases plasma concentration of Lignocaine; increased risk of ventricular arrhythmias. ADVICE: Avoid concomitant use.MajorLoratadineAmiprenavir possibly increases plasma concentration of Loratidine.MethadoneAmprenavir reduces plasma concentration of methodone.Methysergide (Hydrogen Maleate)Increased risk of ergotism when Amprenavir given with Methysergide. ADVICE: Avoid concomitant use.MajorMidazolamIncreased risk of prolonged sedation and respiratory depression when Amprenavir given with Midazolam.Phenytoin (Na)Plasma concentration of Amprenavir possibly reduced byv Phenytoin.PimozideAmprenavir increases plasma concentration of Sertindole; increased risk of ventricular arrhythmias. ADVICE: Avoid concomitant use.Propafenone (HCl)Amprenavir possibly increases plasma concentration of Propafenone; increased risk of ventricular arrhythmias. ADVICE: Avoid concomitant use.MajorQuinidineAmprenavir possibly increases plasma concentration of quinidine; increased risk of ventricular arrhythmias. ADVICE: Avoid concomitant use.MajorRifabutinAmprenavir increases plasma concentration of Rifabutin. MajorReduce dose of RifabutinRifampicinPlasma concentration of Amprenavir significantly reduced by Rifampicin. ADVICE: Avoid concomitant use.MajorSertindoleAmprenavir increases plasma concentration of Sertindole; increased risk of ventricular arrhythmias. ADICE: Avoid concomitant use.MajorSimvastatinAmprenavir possibly increases plasma concentration of Simvastatin. ADVICE: Avoid concomitant use.MajorTerfenadineIncreased risk of ventricular arrhythmias when Amprenavir given with Terfenadine. ADVICE: Avoid concomitant use.MajorVORICONAZOLEincrease the serum concentration of amprenavir by decreasing its metabolismdiscontinued or dose changed These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

caps, Solutions Store in a well closed container, at room temperature, . Protect from Sunlight, Moisture and Heat.

Amprenavir should be used with caution in patients with hepatic impairment (May need dose reduction); pregnancy (use only if potential benefit outweighs risk); diabetes; haemophilia; avoid vitaminE suppliments (vit.E included in formulation); oral solution contains propylene glycol----avoid in hepatic impairment, in severe renal impairment, in pregnancy, and avoid concomitant metronidazole, disulfiram, or preparation containing alcohol or propylene glycol; increased susceptibility to propylene glycol toxicity in slow metaboliser.RASH: Rash may occur, usually in the second week of therapy; discontinue permanently if severe rash with systemic or allergic symptoms or, mucosal involvement; if rash mild or moderate, may continue without interruption----rash usally resolves within two weeks and may respond to antihistamines.